Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Parent Danaher (DHR) group FY2025 revenue $24.57bn (+3.0%); operating margin 19.1%; net income $3.60bn.
Figures cover the whole listed group, not this business alone.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Leica Biosystems found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches or cyber incidents involving Leica Biosystems found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Apr 2025: Leica Biosystems began a US FDA Class 2 recall of 77 HistoCore PELORIS 3 tissue processors over a leak in manifold tubing; more serial numbers were added in Aug 2025 and the recall is listed as open.
Contract delivery, go-lives, terminations and disputes.
Sep 2025: trusts in the South West London Pathology network selected Leica Biosystems' Aperio GT 450 DX scanners with Indica Labs' HALO AP for digital pathology, funded through NHS England's diagnostics digital capability programme.